Section 16 · Monograph
Vamorolone
Reviewed Nov 2026FDA label
AgamreeDissociative steroid
- Forms
- Oral susp: 40mg/mL
- Dose
- Weight-based once daily, approx 6mg/kg/day (DMD, age 2+)
- MOA
- Glucocorticoid/mineralocorticoid receptor modulation with reduced transactivation
Indications
- Treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and olderFDA-labeled
Mechanism of Action
- Dissociative steroid that binds glucocorticoid and mineralocorticoid receptors, retaining anti-inflammatory transrepression with reduced transactivation-related adverse effects
Full Dosing
Adult / usual
- Weight-based oral suspension once daily with food (approximately 6mg/kg/day)
- Taper when discontinuing; review vaccinations before starting
Hepatic
- Confirm the exact weight-band dose and hepatic-impairment adjustments against the current prescribing information
Contraindications
- Known hypersensitivity to vamorolone or its excipients
Drug Interactions
- Strong CYP3A4 inhibitors and inducers may require dose adjustment or avoidance
- Live vaccines should be timed appropriately
Adverse Effects
- Cushingoid features, vomiting, weight gain
- Psychiatric and behavioral changes
- Adrenal suppression
- Infection risk
- Bone and growth effects (growth suppression was less than with prednisone in trials)
Monitoring Parameters
- Growth, blood pressure, glucose, bone health
- Behavior and mood
- Adrenal suppression on withdrawal
Pregnancy & Lactation
- Limited data; weigh risks and benefits